about
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare CostsAnalysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of double-refractory multiple myeloma.
@en
type
label
Management of double-refractory multiple myeloma.
@en
prefLabel
Management of double-refractory multiple myeloma.
@en
P2860
P1476
Management of double-refractory multiple myeloma.
@en
P2093
Jason P Meadows
Tomer M Mark
P2860
P2888
P304
P356
10.1007/S11899-013-0173-2
P577
2013-12-01T00:00:00Z
P6179
1018197004